Drug repositioning for the discovery of therapeutic approaches for pulmonary arterial hypertension

• Project/Area Number: 19K23987
• Research Category: Grant-in-Aid for Research Activity start-up
• Allocation Type: Multi-year Fund
• Review Section: 0903:Organ-based internal medicine and related fields
• Research Institution: Tohoku University
• Principal Investigator: Siddique MohammadAbdulHai 東北大学, 大学病院, 学術研究員 (50849453)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Project Status: Granted (Fiscal Year 2019)
• Budget Amount: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000); Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 薬理学一般 / 循環器内科学

Outline of Research at the Start

Pulmonary arterial hypertension (PAH) is a fatal disease with a 20% 5-years survival rate without treatment. Importantly, early diagnosis method is very rare in pulmonary hypertension, which is confirmed at the mild stage except in special cases such as family onset, and usually the diagnosis of pulmonary hypertension is confirmed after finally progressed. The purpose of this study is to discover new drugs for pulmonary hypertension with antiproliferative effects on VSMCs from patients with PAH by drug repositioning of existing drugs.